Conclusion MOCO-LGE is superior to bh-LGE in a clinical service, with better image quality, easier interpretation and faster scanning times. Results Of the 67 patients (age 54±19 years, 47 male), 17 had ICDs, 9 cardiac resynchronisation devices, 19 pacemakers and 22 implantable loop recorders (ILR). 20 (44%) pulse generators were non-conditional; 11 (16%) inpatients; 10 (15%) with AF; 7 (10%) pacing dependent. Every patient referred was scanned successfully. 10 leads had parameter changes by Magnasafe criteria with no clinical significance, and 80% normalising at follow up (66±40 days).
Background There is a growing need for CMR in patients with implanted devices, who represent a high-risk cohort. Recent reports suggest CMR may be safely performed but artefact remains a significant limitation to late gadolinium enhancement (LGE). It is still unknown whether novel sequences to reduce artefact can be used efficiently or provide clinically useful information from scar imaging. Methods We used a novel free-breathing wideband MOCO sequence with PSIR (WB-MOCO) designed for a clinical environment. Patients with implantable cardiac devices (including MR non-conditional) referred clinically for CMR were scanned according to local standard operating procedure (based on national guidelines and Magnasafe Registry). WB-MOCO LGE approach was used primarily, with paired comparator conventional PSIR FLASH LGE or free breathing MOCO SSFP. Conventional and WB-MOCO LGE were assessed for artefact on a scale of 0 to 4 (0=no artefact, 4=completely obscured). A panel of three CMR cardiologists judged impact on patient care. Results Of the 67 patients (age 54±19 years, 47 male), 17 had ICDs, 9 cardiac resynchronisation devices, 19 pacemakers and 22 implantable loop recorders (ILR). 20 (44%) pulse generators were non-conditional; 11 (16%) inpatients; 10 (15%) with AF; 7 (10%) pacing dependent. Every patient referred was scanned successfully. 10 leads had parameter changes by Magnasafe criteria with no clinical significance, and 80% normalising at follow up (66±40 days).
With conventional LGE imaging, 22 (33%) scans were nondiagnostic. WB-MOCO LGE completely removed artefact in 19 (87%), and achieved diagnosis in the remaining 3. 10 (15%) patients had significant artefact on conventional LGE, which WB completely or almost completely removed.
Overall, CMR with WB-MOCO LGE changed management in an additional 26 (39%) patients compared to CMR with conventional LGE (33 patients, 49%). This benefit was in 77% of defibrillators, 25% of pacemakers and 5% of the ILR groups. Conclusion The WB-MOCO sequence permits high quality LGE imaging in device patients, and is robust enough for a clinical setting. This adds clinical utility particularly in defibrillator patients, also pacemaker patients but with limited utility in ILRs. Our electrophysiology department has now incorporated this into their protocol prior to ventricular tachycardia ablation. Objectives Cardiac failure caused by transthyretin amyloidosis (ATTR) is an underdiagnosed clinical entity which has an important overlapping clinical phenotype with hypertrophic cardiomyopathy (HCM). Native myocardial T1 mapping by CMR is useful for diagnosis in cardiac amyloidosis. Here, we investigate the diagnostic and prognostic value of T1 mapping in the largest ATTR population studied so far as well as patients with HCM. We aimed to: 1) assess the ability of native T1 to diagnose cardiac amyloidosis; 2) compare native T1 to extracellular volume (ECV), and; 3) stratify prognosis. Methods 134 wild-type ATTR (ATTRwt) (122 males, age 76 ±7 years), 95 mutant-type (ATTRm) (64 males, age 66±12 years) and 12 mutation carriers (4 males, age 46±8 years) were compared to 44 HCM patients. All subjects underwent CMR with standard SSFP-cine imaging, T1 mapping and ECV measurement. ATTR patients underwent 99m Tc-DPD scintigraphy, the current diagnostic imaging reference standard for ATTR, with uptake determined by semi-quantitative score. Results Native T1 and ECV were elevated in ATTR compared to HCM (p<0.001) (mean T1: in ATTRwt 1091±52 ms, in ATTRm 1084±68 ms, in HCM 1026±64 ms; mean ECV: in ATTRwt 0.6±0.1, in ATTRm 0.58±0.2 ms, in HCM 0.38 ±0.1 ms). No significant difference between native T1 and ECV was found between ATTRwt and ATTRm. Native T1 and ECV diagnostic performance was similar for ATTRwt and ATTRm (vs HCM: T1 AUC 0.89; ECV AUC 0.93; p=0.11 Abstract 014 Figure 1 Conventional LGE (le4) with device ar-fact and WB MOCO LGE revealing a large apical thrombus secondary to a large LAD infarct (right).
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Abstract 015 Figure 1 Diagnostic performance and prognostic capability. (A) Receiver operator characteristics curve (ROC) for the discrimination of possible or definite transthyretin (ATTR) cardiac amyloidosis by native T1 and ECV from HCM. Kaplan-Meier survival curves for (B) pre-contrast myocardial T1 and (C) extracellular volume at bolus. The median native myocardial T1 (1092ms) (B) and median extracellular volume (ECV) (0.61) (C) were used as the respective cut points for survival.
